Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Astelin Nasal Spray 01 Azelastine Hydrochloride

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 5/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

50%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Phase 1 (1)
Phase 3 (1)

Trial Status

Completed1
Not Yet Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT00783432Phase 3CompletedPrimary

Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic Rhinitis

SYF35af905bdd184ebe816ca4b582d83ff2Phase 1Not Yet Recruiting

Clinical trial to evaluate the safety, tolerability and effectiveness of a medicinal nasal insert in the treatment of chronic hay fever.- Inspicare

Showing all 2 trials

Research Network

Common Treatments

  • Astelin Nasal Spray 01 Azelastine Hydrochloride1
  • Astepro Nasal Spray 01 Azelastine Hydrochloride1

Active Sponsors

  • Meda Pharmaceuticals1
  • Dianosic1

Top Investigators

Related Conditions

  • Nonallergic Rhinitis1

Activity Timeline